<DOC>
	<DOC>NCT00605475</DOC>
	<brief_summary>The purpose of this study was to evaluate, in patients with Type 2 Diabetes Mellitus, whether Canakinumab can lower Glycosylated hemoglobin / hemoglobin A1c (HbA1c) and/or peak glucose levels in response to an oral glucose tolerance test (OGTT).</brief_summary>
	<brief_title>Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACZ885 in Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Male or female patients aged 18 to 70 years, with type 2 diabetes mellitus (noninsulin dependent diabetes) for at least 6 months prior to study start HbA1c between 7.0 and 9.5% On stable dose metformin monotherapy Stable body weight Poorly controlled type 2 diabetes (very low or very high blood sugar levels, or other indicators of poor control) Acute infections prior to dosing Patients with type 1 diabetes (insulindependent diabetes) Taking diabetes medication (other than metformin) Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Type 2 Diabetes Mellitus</keyword>
	<keyword>Canakinumab</keyword>
	<keyword>ACZ885</keyword>
	<keyword>IL-1B antagonist</keyword>
	<keyword>metformin</keyword>
	<keyword>glycemic control</keyword>
	<keyword>insulin sensitivity</keyword>
</DOC>